Clinical Trial Update: Efficacy and Safety of a 7.5% Icodextrin Peritoneal Dialysis Solution in Once-Daily Long Dwell Exchange [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating the efficacy and safety of a 7.5% icodextrin peritoneal dialysis solution in once-daily long-dwell exchanges has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease

Drugs mentioned

• Icodextrin 7.5% peritoneal dialysis solution (icodextrin)

Snippet

Sponsor: Shanghai Jiao Tong University School of Medicine | Conditions: Chronic Kidney Disease, Peritoneal Dialysis | Phase 4 | Status: COMPLETED